Platelet to lymphocyte ratio as a new prognostic for patients with metastatic renal cell cancer

Basit Öğe Kaydı
dc.contributor.authorGündüz, Şeyda Gülenay
dc.contributor.authorMutlu, Hasan
dc.contributor.authorTural, Deniz
dc.contributor.authorYıldız, Özcan
dc.contributor.authorUysal, Mükremin
dc.contributor.authorÇoşkun, Hasan Şenol
dc.contributor.authorBozcuk, Hakan Şat
dc.date.accessioned10.07.201910:49:13
dc.date.accessioned2019-07-10T19:36:37Z
dc.date.available10.07.201910:49:14
dc.date.available2019-07-10T19:36:37Z
dc.date.issued2015
dc.departmentİstanbul Medipol Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, İç Hastalıkları Ana Bilim Dalı
dc.description.abstractAim: The objective of this study was to evaluate the blood platelet-lymphocyte ratio (PLR) for its prognostic value in patients with metastatic renal cell cancer (RCC). Methods: We retrospectively reviewed 100 patients diagnosed with metastatic RCC previously treated with tyrosine kinase inhibitors from three centers. We assessed the prognostic value of pretreatment PLR and other clinical and laboratory parameters based on univariate and multivariate analyses. Results: Median progression-free survival (PFS) was 7.3 months and median overall survival (OS) was 15.3 months. Multivariate analysis revealed that PFS is significantly affected by ECOG PS (P=0.047), PLR (P=0.029) and calcium level (P=0.023). Median PFS was 13.9 versus 5.3 months in patients with PLR?210 versus PLR>210 (log rank; P=0.001). Median OS was 25.9 versus 10.9 months with PLR?210 versus PLR>210 (log rank; P=0.013). Conclusions: This study shows that increased pretreatment PLR is an independent prognostic indicator in patients with metastatic RCC who use tyrosine kinase inhibitors.
dc.identifier.citationGündüz, Ş. G., Mutlu, H., Tural, D., Yıldız, Ö., Uysal, M., Çoşkun, H. Ş. ... Bozcuk, H. Ş. (2015). Platelet to lymphocyte ratio as a new prognostic for patients with metastatic renal cell cancer. Asia-Pacific Journal of Clinical Oncology, 11(4), 288-292. https://dx.doi.org/10.1111/ajco.12358
dc.identifier.doi10.1111/ajco.12358
dc.identifier.endpage292
dc.identifier.issn1743-7555
dc.identifier.issn1743-7563
dc.identifier.issue4
dc.identifier.scopusqualityQ2
dc.identifier.startpage288
dc.identifier.urihttps://hdl.handle.net/20.500.12511/1212
dc.identifier.urihttps://dx.doi.org/10.1111/ajco.12358
dc.identifier.volume11
dc.identifier.wosqualityQ4
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherWiley-Blackwell
dc.relation.ispartofAsia-Pacific Journal of Clinical Oncologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/embargoedAccess
dc.subjectMetastatic Renal Cell Carcinoma
dc.subjectPlatelet to Lymphocyte Ratio
dc.subjectPrognosis
dc.titlePlatelet to lymphocyte ratio as a new prognostic for patients with metastatic renal cell cancer
dc.typeArticle

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
uysal, mukremin-2015.pdf
Boyut:
310.24 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text
İndir

Koleksiyon

Scopus İndeksli Yayınlar Koleksiyonu
Makale Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu